Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets two FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visitwww.assertiotx.com.
Company profile
Website
CEO
Arthur Joseph Higgins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Depomed Inc
SEC CIK
Corporate docs
Subsidiaries
Depo DR Sub, LLC • Depo NF Sub, LLC • Depomed Bermuda Ltd ...
IRS number
943229046
Latest filings (excl ownership)
15-12B
Securities registration termination
18 Jun 20
8-K
Entry into a Material Definitive Agreement
22 May 20
25-NSE
Exchange delisting
19 May 20
DEFA14A
Additional proxy soliciting materials
18 May 20
10-Q
2020 Q1
Quarterly report
11 May 20
8-K
Assertio Therapeutics Announces First-Quarter 2020 Results
11 May 20
425
Business combination disclosure
11 May 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Apr 20
425
Business combination disclosure
21 Apr 20
8-K
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting
21 Apr 20
Latest ownership filings
SC 13G/A
Allianz Global Investors U.S. Holdings LLC
12 Feb 21
4
KAREN A DAWES
11 May 20
4/A
Stan Bukofzer
3 Apr 20
4
Stan Bukofzer
3 Apr 20
4
James Galeota JR
31 Mar 20
SC 13D
Zyla Life Sciences
26 Mar 20
4
Heather L Mason
19 Feb 20
SC 13G/A
Assertio Therapeutics, Inc
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Assertio Therapeutics, Inc
13 Feb 20
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|